2018 - Fellow, National Academy of Inventors
2011 - Fellow of the American Association for the Advancement of Science (AAAS)
Prakash S. Nagarkatti mainly investigates Immunology, Immune system, Cancer research, Apoptosis and Inflammation. Prakash S. Nagarkatti interconnects Receptor and Cytotoxic T cell in the investigation of issues within Immunology. As a part of the same scientific study, Prakash S. Nagarkatti usually deals with the Immune system, concentrating on Cannabinoid receptor and frequently concerns with Cannabinoid and Endocannabinoid system.
His studies in Cancer research integrate themes in fields like Bryostatin, Aryl hydrocarbon receptor, Latent Virus and Rottlerin. His Apoptosis research integrates issues from Internal medicine, In vitro, Endocrinology and Cell biology. The various areas that Prakash S. Nagarkatti examines in his Inflammation study include Colitis and Resveratrol.
His main research concerns Immunology, Immune system, Inflammation, Cancer research and Internal medicine. The Immunology study combines topics in areas such as Cytotoxic T cell and Pharmacology. As part of the same scientific family, Prakash S. Nagarkatti usually focuses on Immune system, concentrating on Cannabinoid receptor and intersecting with Endocannabinoid system.
Prakash S. Nagarkatti works mostly in the field of Inflammation, limiting it down to topics relating to Colitis and, in certain cases, Ulcerative colitis, Inflammatory bowel disease and Colorectal cancer. He studied Cancer research and microRNA that intersect with Gene expression and Epigenetics. His Internal medicine course of study focuses on Endocrinology and Apoptosis, CD8, Toxicity and Thymocyte.
Prakash S. Nagarkatti focuses on Inflammation, Cancer research, Immune system, FOXP3 and Pharmacology. His Inflammation research incorporates elements of Cytokine, Downregulation and upregulation, Colitis and Inflammatory bowel disease. His studies deal with areas such as T cell, Apoptosis, microRNA, Myeloid-derived Suppressor Cell and Resveratrol as well as Cancer research.
His study with Immune system involves better knowledge in Immunology. His study in Immunology is interdisciplinary in nature, drawing from both Microbiome and ARDS. Prakash S. Nagarkatti usually deals with FOXP3 and limits it to topics linked to Aryl hydrocarbon receptor and Cell biology and Carcinogen.
His scientific interests lie mostly in Inflammation, Cancer research, Gut flora, Immune system and Immunology. Prakash S. Nagarkatti has included themes like Downregulation and upregulation, Colitis, Cytokine and Resveratrol in his Inflammation study. He combines subjects such as Apoptosis and FOXP3 with his study of Resveratrol.
His Cancer research study combines topics from a wide range of disciplines, such as T cell, Aryl hydrocarbon receptor, Chemokine, Transforming growth factor beta and Effector. His research integrates issues of Gene expression profiling, Peripheral blood mononuclear cell, Interleukin, Regulation of gene expression and Epigenetics in his study of Immune system. Prakash S. Nagarkatti is involved in the study of Immunology that focuses on Multiple sclerosis in particular.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Cannabinoids as novel anti-inflammatory drugs
Prakash Nagarkatti;Rupal Pandey;Sadiye Amcaoglu Rieder;Venkatesh L Hegde.
Future Medicinal Chemistry (2009)
Role of cytokines as a double-edged sword in sepsis.
Hina Chaudhry;Juhua Zhou;Juhua Zhou;Yin Zhong;Mir Mustafa Ali.
in Vivo (2013)
Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease
Robert J McKallip;Catherine Lombard;Michael T Fisher;Billy R Martin.
Deoxycholic Acid (DCA) Causes Ligand-independent Activation of Epidermal Growth Factor Receptor (EGFR) and FAS Receptor in Primary Hepatocytes: Inhibition of EGFR/Mitogen-activated Protein Kinase-Signaling Module Enhances DCA-induced Apoptosis
Liang Qiao;Elaine Studer;Kevin Leach;Robert McKinstry.
Molecular Biology of the Cell (2001)
Δ-9-Tetrahydrocannabinol Enhances Breast Cancer Growth and Metastasis by Suppression of the Antitumor Immune Response
Robert J. McKallip;Mitzi Nagarkatti;Prakash S. Nagarkatti.
Journal of Immunology (2005)
Activation of aryl hydrocarbon receptor (AhR) leads to reciprocal epigenetic regulation of FoxP3 and IL-17 expression and amelioration of experimental colitis.
Narendra P. Singh;Udai P. Singh;Balwan Singh;Robert L. Price.
PLOS ONE (2011)
Bryostatin Modulates Latent HIV-1 Infection via PKC and AMPK Signaling but Inhibits Acute Infection in a Receptor Independent Manner
Rajeev Mehla;Shalmali Bivalkar-Mehla;Ruonan Zhang;Indhira Handy.
PLOS ONE (2010)
Cannabinoid-induced apoptosis in immune cells as a pathway to immunosuppression
Sadiye Amcaoglu Rieder;Ashok Chauhan;Ugra Singh;Mitzi Nagarkatti.
Resveratrol Suppresses Colitis and Colon Cancer Associated with Colitis
Xiangli Cui;Yu Jin;Anne B. Hofseth;Edsel Pena.
Cancer Prevention Research (2010)
Resveratrol (trans-3,5,4'-trihydroxystilbene) ameliorates experimental allergic encephalomyelitis, primarily via induction of apoptosis in T cells involving activation of aryl hydrocarbon receptor and estrogen receptor.
Narendra P. Singh;Venkatesh L. Hegde;Lorne J. Hofseth;Mitzi Nagarkatti.
Molecular Pharmacology (2007)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: